Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean? - Annals of Oncology
Prostate cancer | Nature Reviews Disease Primers
Genomic correlates of clinical outcome in advanced prostate cancer
Genomic correlates of clinical outcome in advanced prostate cancer. - Abstract - Europe PMC
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact | Nature Communications
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer - European Urology
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited - ScienceDirect
Clinical implications of genomic alterations in metastatic prostate cancer | Prostate Cancer and Prostatic Diseases
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer - European Urology
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer | Scientific Reports
PDF) Genomic correlates of clinical outcome in advanced prostate cancer
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer | JCO Precision Oncology
Prostate cancer - The Lancet
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis - ScienceDirect
Integrative Clinical Genomics of Advanced Prostate Cancer - ScienceDirect
Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features - Clinical Oncology
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase - eBioMedicine
